Guided Therapeutics (GTHP) Total Non-Current Liabilities (2013 - 2025)

Guided Therapeutics has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $694000.0 for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $694000.0, up 519.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $694000.0 (up 519.64% YoY), and the FY2025 annual result was $694000.0, up 519.64% from the prior year.
• Total Non-Current Liabilities came in at $694000.0 for Q4 2025 at Guided Therapeutics, up from $79000.0 in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 million in Q4 2021 to a low of $35000.0 in Q2 2025.
• The 5-year median for Total Non-Current Liabilities is $710500.0 (2023), against an average of $870950.0.
• Across the five-year window, Total Non-Current Liabilities plunged 90.6% in 2024 and soared 519.64% in 2025, its largest moves.
• Guided Therapeutics' Total Non-Current Liabilities stood at $1.8 million in 2021, then retreated by 22.95% to $1.4 million in 2022, then tumbled by 51.74% to $666000.0 in 2023, then sank by 83.18% to $112000.0 in 2024, then jumped by 519.64% to $694000.0 in 2025.
• The last three Total Non-Current Liabilities figures came in at $694000.0 (Q4 2025), $79000.0 (Q3 2025), and $35000.0 (Q2 2025), per Business Quant data.